Amgen Inc. (AMGN)
$
345.46
+0.89 (0.26%)
Key metrics
Financial statements
Free cash flow per share
21.4480
Market cap
185.5 Billion
Price to sales ratio
5.1599
Debt to equity
5.6749
Current ratio
1.2797
Income quality
1.8738
Average inventory
6.5 Billion
ROE
0.9619
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Amgen Inc. is a global biotechnology company that discovers, develops, manufactures, and delivers human therapeutics focusing on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience. The company reported an income before tax of $4,609,000,000.00 showcasing its pre-tax profitability. The EBITDA is $13,356,000,000.00 a key indicator of the company's operational profitability, while the operating income ratio is 0.22 indicating the company's operational profitability margin. Additionally, the gross profit ratio is 0.62 reflecting the efficiency of the company's production and sales operations. The company's stock is identified with the symbol 'AMGN' in the market, representing a significant asset for investors. Amgen's product portfolio includes treatments such as Enbrel for plaque psoriasis and rheumatoid arthritis, Neulasta for patients with low white blood cell counts due to cancer, Prolia for osteoporosis in postmenopausal women, and Repatha to reduce cardiovascular risks, among others. It also engages in several collaboration agreements to develop innovative therapies, such as its partnership with Novartis Pharma AG and Kyowa Kirin Co., Ltd. Trading at a price of $285.41 the stock is positioned in the higher-end market, reflecting the company's strong market presence. Furthermore, the stock has a high average trading volume of 2,624,169.00 indicating strong liquidity and investor interest. With a large market capitalization of $186,023,532,604.00 the company is a dominant player in the biotechnology industry, contributing significantly to the overall market landscape. Amgen Inc. operates within the Healthcare sector, driving innovation and growth through its cutting-edge research and product development. Its offerings, including Otezla, Aranesp, and KYPROLIS, illustrate its commitment to providing impactful therapies for various health conditions. By serving healthcare providers across multiple channels, including hospitals and pharmacies, Amgen focuses on delivering solutions that enhance patient outcomes. The company's collaborations with firms like Neumora Therapeutics and Plexium underscore its strategic approach to expanding its therapeutic portfolio, positioning it to remain a key player in a constantly evolving industry.
Is Amgen Inc. (AMGN) a good investment?
Investing in Amgen Inc. (AMGN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B+, with a Bullish outlook. Always conduct your own research before investing.
What is Amgen Inc. (AMGN)'s stock forecast?
Analysts predict Amgen Inc. stock to fluctuate between $253.30 (low) and $345.84 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Amgen Inc.'s market capitalization?
As of 2025-11-28, Amgen Inc.'s market cap is $186,023,532,604, based on 538,480,671 outstanding shares.
How does Amgen Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Amgen Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Amgen Inc. pay dividends?
Amgen Inc. pays dividends. The current dividend yield is 2.82%, with a payout of $2.38 per share.
How can I buy Amgen Inc. (AMGN) stock?
To buy Amgen Inc. (AMGN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for AMGN. Place an order (Market, Limit, etc.).
What is the best time to invest in Amgen Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Amgen Inc. stock ever split?
Amgen Inc.'s last stock split was 2:1 on 1999-11-22.
How did Amgen Inc. perform in the last earnings report?
Revenue: $33,424,000,000 | EPS: $7.62 | Growth: -39.33%.
Where can I find Amgen Inc.'s investor relations reports?
Visit https://www.amgen.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Amgen Inc.?
You can explore historical data from here
What is the all-time high and low for Amgen Inc. stock?
All-time high: $346.85 (2024-07-25) | All-time low: $198.64 (2021-12-01).
What are the key trends affecting Amgen Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
THOUSAND OAKS, Calif. , Nov. 24, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2025 Global Healthcare Conference at 1:45 p.m.
zacks.com
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
investors.com
Despite low relative strength, medical stocks had solid entries in a choppy market.
youtube.com
Bill Baruch, founder and president at Blue Line Capital, joins CNBC's “Halftime Report” to detail his latest Amgen purchase. The Investment Committee debate the biotech sector.
youtube.com
Jim Cramer breaks down why he's keeping an eye on shares of Amgen.
fool.com
An analyst bumped his price target higher on the shares. He didn't change his recommendation, however.
investors.com
Merck said Saturday its new pill — a potential rival to Regeneron and Amgen — lowered stubbornly high cholesterol by almost 60%.
prnewswire.com
Study Also Shows 36% Reduction in Risk of Heart Attack Repatha is the First and Only PCSK9 Inhibitor to Significantly Reduce the Risk of First Heart Attack and Stroke THOUSAND OAKS, Calif. , Nov. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha® (evolocumab) achieved statistically significant and clinically meaningful reductions in major adverse cardiovascular events (MACE) in high-risk adults without a prior heart attack or stroke, when added to statins or other low-density lipoprotein cholesterol (LDL-C)–lowering treatments.
reuters.com
Adding Amgen's cholesterol drug Repatha to standard therapy reduced major cardiovascular events by 25% for at-risk patients who have never had a heart attack or stroke, according to results from a large study presented on Saturday.
seekingalpha.com
Amgen is a biotech leader with strong sales growth, key products outperforming, and an impressive R&D pipeline fueling future prospects. Despite political headwinds and margin pressures, AMGN raised full-year guidance and is implying resilient bottom-line growth. The stock trades at a significant valuation discount to sector peers, making AMGN an attractive value play in the current environment.
See all news
